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Abstract
Background: Multi-vessel disease is frequent in patients presenting with myocardial infarction and have an
important prognostic impact. The decision to proceed to revascularization in non-culprit vessels can be postponed
until ischemia is proven in non-invasive stress tests. On the other hand, there is an increasing evidence to support
the role of fractional flow reserve (FFR) in acute coronary syndrome setting.
Case presentation: We report a case in which a FFR-guided strategy for non-culprit vessels, 3 weeks after an
ST-segment elevation myocardial infarction, was followed by a short-term sub-occlusion of the evaluated vessel.
Conclusion: The timing of the coronary microcirculation recovery post-myocardial infarction, avoiding a possible
false negative FFR, and the diagnostic gaps between ischemia and plaque vulnerability are under discussion. An
FFR-guided strategy in this setting should be interpreted with caution.
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Background
The prevalence of multi-vessel disease (MVD) in pa-
tients presenting with acute ST-segment elevation myo-
cardial infarction (STEMI) approaches 40 % [1]. This
subgroup of STEMI patients has a higher risk of major
adverse cardiac events (MACE) in the first year after pri-
mary percutaneous coronary intervention (PCI) [2].
Therefore, the assessment of the actual severity of the
non-culprit coronary artery stenosis and its optimal
treatment is clinically important soon after primary PCI.
Case presentation
A 79-year-old female with a history of hypertension and
dyslipidaemia, was admitted for an inferior STEMI and
underwent primary angioplasty of the right coronary
artery with implantation of a 3.0 × 33 mm Xience™
everolimus-eluting stent. The emergency coronary angi-
ography also showed three intermediate stenosis in the
mid-segment of the left anterior descending artery
(LAD) – Fig. 1. Transthoracic echocardiogram demon-
strated normal biventricular systolic function with a left
ventricular ejection fraction of 60 %. The patient was
clinically stable and was discharged 4 days later with op-
timized medical therapy (aspirin 100 mg qd, ticagrelor
90 mg bid, atorvastatin 40 mg qd, carvedilol 6.25 mg
bid, ramipril 1.25 mg qd, pantoprazol 40 mg qd).
In order to assess the hemodynamic relevance of the
LAD lesions, a 3 week scheduled coronary angiography
with fractional flow reserve (FFR) measurements of LAD
was performed (Fig. 2), using a 0.014″ pressure guide
wire (PressureWire Aeris™, St Jude Medical, Uppsala,
Sweden). Resting distal coronary pressure to aortic pres-
sure ratio (Pd/Pa) was 0.94. FFR was 0.87, indicating
physiologically non-significant stenosis. There was no
damping of the proximal aortic pressure trace, ensuring
an accurate FFR measurement.
Two months later, the patient was admitted for an an-
terior STEMI and the emergency coronary angiography
revealed a sub-occlusion of the mid-LAD (Fig. 3). The le-
sion was treated with a 3.0 × 15 mm Xience™ everolimus-
eluting stent. Right coronary angiography showed neither
restenosis in the previously implanted stent nor other
significant coronary lesions. The patient assured having
good compliance with the therapeutic regimen since the
first cardiovascular event.* Correspondence: luispcleite@gmail.comDepartament of Cardiology, Centro Hospitalar e Universitário de Coimbra,
Praceta Prof. Mota Pinto, Coimbra 3000-075, Portugal
© 2015 Leite et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Leite et al. BMC Cardiovascular Disorders  (2015) 15:127 
DOI 10.1186/s12872-015-0122-1
Discussion
In patients with STEMI and MVD, the current recom-
mendations state that primary PCI should be limited to
the culprit vessel with the exception of cardiogenic
shock in the presence of multiple, critical stenosis
or highly unstable lesions, and if there is persistent
ischemia after PCI on the supposed culprit lesion [3]. If
staged PCI to non-culprit vessels is being considered,
non-invasive stress testing (myocardial perfusion scintig-
raphy, stress echocardiography, positron emission tom-
ography or magnetic resonance imaging) should be used
for ischemia and viability testing prior to a decision to
proceed with PCI [4].
Fractional flow reserve is a well-validated technique to
guide coronary intervention by identification of lesion-
level ischemia. In the DEFER study, the prognosis of
intermediate lesions with an FFR of > 0.75 was excellent
if treated medically, with a < 1 % risk of any AMI after
5 years of follow-up [5]. However, studies to date have
mainly involved stable patients outside of acute myocar-
dial infarction (AMI) [5–8]. The use of FFR to assess
culprit and non-culprit lesions in the setting of acute is-
chemia represents a controversial area, although there is
an increasing evidence base to support the role of FFR-
guided strategy in acute coronary syndrome (ACS) [9].
The physiological principles underlying FFR are critically
dependent on the ability to achieve maximal hyperaemia.
In patients with AMI, pathophysiological disturbances in
the microvasculature can have a potential impact on the
ability to induce maximal hyperaemia, and thereby
compromise the accuracy of FFR assessments in non-
culprit vessels, theoretically leading to false negative
results [10]. The 2011 ESC Guidelines for the man-
agement of ACS without ST-segment elevation [11]
recommend that FFR should be ideally performed
more than 5 days after the acute event in order to
minimize the impact of any microvascular disturb-
ance. The 2012 ESC Guidelines for the management
Fig. 1 Coronary angiography in the inferior STEMI. Total occlusion of the proximal-segment of the right coronary artery and three intermediate
stenosis in the mid-segment of the LAD
Fig. 2 Three-week follow-up with coronary angiography and FFR. Coronary angiography showing the intermediate LAD lesions and FFR evaluation
with the result of 0.87
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of STEMI [4] state the staged revascularization ap-
proach for STEMI with MVD can be guided by FFR
if performed several days or weeks after primary PCI.
In the case report presented, the functional assess-
ment of the mid-LAD lesions was made 3 weeks later
than the primary PCI, in concordance to the current
guidelines.
One of the most important studies about the use of FFR
in ACS was from Ntalianis et al. [12] who studied 75 acute
STEMI patients and 26 NSTEMI patients (<72 h post on-
set) and measured FFR in the non-culprit stenosis immedi-
ately following PCI of the culprit vessel and then repeated
the FFR at 35 ± 4 days post initial procedure. The FFR value
remained unchanged between the acute and follow-up
phases in patients with STEMI (0.78 ± 0.10 vs. 0.76 ± 0.10,
p =NS) and NSTEMI (0.77 ± 0.10 vs. 0.77 ± 0.20, p =NS).
In only 2 patients, the FFR value was higher than
0.80 at the acute phase and lower than 0.75 at
follow-up. The authors stated the data support that
FFR measurements are safe and reliable for evaluating
the severity of non-culprit stenosis in the acute phase
of ACS, even during primary PCI.
A more recent study from Cuculi et al. [13] performed
an invasive assessment of coronary physiology in 82
STEMI patients, immediately following PCI of the
culprit vessel and 6 months later, associated with a
contrast-enhanced cardiac magnetic resonance imaging
evaluation of microvascular obstruction. Baseline Pd/Pa
remained stable over time, but FFR reduced significantly
between primary PCI and 6 months (p = 0.008); this re-
duction was mainly observed in patients with micro-
vascular obstruction. Therefore, the authors stated that
coronary microcirculation recovery progresses further by
6 months, suggesting that using FFR soon after STEMI
might underestimate the degree of non-culprit vessel
stenosis in almost half of patients.
The index of microcirculatory resistance (IMR) is a
validated invasive wire-based measure of microvascula-
ture function [14] and could be useful to assess the
status of the coronary microcirculation in the setting of
AMI [15], which may be used to validate an FFR result.
The other potential caveat in a FFR-guided strategy in
ACS patients, as it was done in our case report, is the
possible existence of vulnerable coronary plaques in
absence of flow limitation [9]. In the Providing Regional
Observations to Study Predictors of Events in the Cor-
onary Tree (PROSPECT) study [16], patients presenting
with ACS in whom PCI was successful, underwent 3-
vessel radiofrequency intravascular ultra-sound (IVUS)
imaging, and were followed for a median of 3.4 years for
the incidence of MACE. In this study, the non-culprit le-
sions that led to MACE were frequently mild on angio-
graphic assessment, but most were characterized by a
large plaque burden, a small luminal area and were thin-
cap fibroatheromas (TCFA); no MACE arose from un-
treated segments with a plaque burden resulting in less
than 40 % loss of cross-sectional luminal area. Using
data from PROSPECT study, some authors stated that
clinical and angiographic characteristics had poor pre-
dictive accuracy in identifying patients with untreated
high-risk plaques, at least not enough to obviate the need
for intracoronary-imaging, although they assume that it is
unrealistic to applicate 3-vessel invasive imaging in every
clinical setting [17]. Others authors divided the same co-
hort into quartiles according to baseline angiographic
diameter stenosis and concluded that the triad of
predictors of future MACE increased in frequency with
increasing angiographic diameter stenosis [18].
Some points of controversy involve the risk assessment
of future MACE: do we have a cross-link between ische-
mia and plaque vulnerability? Can we expect that
plaques with higher FFR values are stable and that lower
FFR, with repetitive ischemia and high shear stress, in-
duce vulnerability? Or do we have a diagnostic gap of
vulnerable plaque between physiology and morphology?
A study from Versteeg et al. [19] demonstrated that
monocyte toll-like receptors 2 and 4 related to plaque
vulnerability were significantly higher in patients with
Fig. 3 Coronary angiography in the anterior STEMI. Sub-occlusion of the mid-LAD and right coronary artery without significant lesions
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FFR < 0.75 than in patients with an FFR measurement
of > 0.80, suggesting that vulnerability may be preceded by
ischemia. In the Fractional Flow Reserve and Intravascular
Ultrasound Relationship Study (FIRST) [20], the aim was
to evaluate the correlation between FFR, IVUS, and virtual
histology (VH) in intermediate coronary lesions. Minimal
lumen area obtained by IVUS showed a moderate correl-
ation with FFR measurements and the optimal cut-off for
a FFR of < 0.80 varied depending on the vessel size. Plaque
composition assessed by VH-IVUS identified only plaque
burden as having any correlation with FFR values. Lesions
without TCFA had better correlation with FFR compared
with lesions with TCFA. A study from Hüseyinova et al.
[21] evaluated 48 non-ST-elevation ACS patients having
paired hemodynamic and morphological data of the cul-
prit vessel. It was demonstrated that for a given stenosis,
FFR values decrease with an increase in necrotic core and
dense calcium contents of the physiologically significant
coronary plaques. However, plaque composition did not
exert any influence on the hemodynamic effect generated
by physiologically non-significant stenosis.
The COMPARE ACUTE trial is an ongoing study
enrolling MVD patients undergoing primary PCI and
randomly allocates patients to receive either FFR-guided
PCI or culprit vessel-only PCI in the setting of STEMI
[22]. This trial may help to define the role of FFR in
STEMI patients with MVD.
Conclusions
The use of FFR to assess non-culprit lesions in AMI
patients is useful to guide treatment if strongly indicative
of ischemia. A negative FFR is this setting should be inter-
preted with caution and may be appropriate to access
plaque vulnerability by intracoronary imaging, to consider
subsequent non-invasive testing or alternatively repeat
FFR at a later date. Further studies are required to stablish
the ideal timing to perform FFR after AMI, in order to
minimize the impact of any microvascular disturbance.
The role of FFR in the assessment of vulnerable plaques
per se also requires additional evaluation in clinical trials.
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